Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
about
Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidenceClinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosisTumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatmentNeuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated EntitiesOverview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndromeCatastrophic outcome of patients with a rebound after Natalizumab treatment discontinuationDefective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammationTreating multiple sclerosis with monoclonal antibodies: a 2013 update.Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Fingolimod after natalizumab and the risk of short-term relapse.Tumefactive demyelination: an approach to diagnosis and management.Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.Neurological safety of fingolimod: An updated reviewS1P1 deletion differentially affects TH17 and Regulatory T cellsThe usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.Pattern Recognition of the Multiple Sclerosis Syndrome.Differential effects of fingolimod on B-cell populations in multiple sclerosis.Reduction of the washout time between natalizumab and fingolimod.Observational Study of Switching from Natalizumab to Immunomodulatory Drugs.Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold.Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others?Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
P2860
Q26752466-4220D7FE-0546-4263-8362-EAD168325D59Q26771635-819142A8-EC97-43F0-B454-9442E8911323Q26777684-CE4ED9AA-BF7D-4EFA-8875-FA43BEAE9C20Q26781389-40FFAFE6-1773-438F-A630-92166DBF99F1Q30458371-218753DF-D194-4CC4-B34C-1E866B55BAF9Q30578046-C8E41E01-520B-4F1C-A1D7-1BF969535C81Q33562198-95FAE32A-02A7-4D3E-BBB5-84FE80E0866BQ33583306-B40E5585-A773-42F8-A20D-8D41C60592F5Q34330211-3CB6DC4D-FA4C-4F3F-8948-D4C111F02C8CQ35547287-12847022-EFE7-4607-84D5-8D4ED611D915Q35659134-9ECFB859-8CFD-4BA5-A245-DAB4B94F1A6FQ36975701-89EB0472-F11D-49A1-A6C5-DFDB664C810DQ37725909-72AA6515-FCF3-4D2A-A48C-1060F45D030CQ38075462-67BFA042-D068-4212-9C69-CEDC69ECFB22Q38152451-C5ED0715-1CA6-4218-A3F8-5027717D5D8BQ38177842-595AB515-8F90-40AD-99FC-7C3A4B8FB2C1Q39320418-AD12BD97-218F-4FCF-AB82-E938DAE2ACFDQ41553443-093A2000-0E49-453C-9A50-A5F2562F78B5Q42374227-029DC9A1-A39E-4C5A-8947-3B0E3CBDE4D2Q44061291-FE707A99-A6E7-4B4C-A61D-A2AA01CEC9EAQ45967844-4AFF36FE-ABD0-458F-B3BE-C4FA5C053BFFQ47096340-563B9FD9-C92C-4782-ADE2-57F2717209C5Q50860736-46C7519A-A1A3-43F2-9348-42ACE199AA49Q50949572-2BE992BC-402B-4D70-B91F-5DAA3575B2CAQ51218322-C90726FA-4782-4D25-A751-BD83A222A48BQ54375890-EEDC0ED2-A128-4F93-90B3-324E0AD7C7CBQ54761661-1B6BB447-16CF-47AE-847E-EC897B451869Q58793277-24E9108C-7805-4DD3-86A0-5B0AB420E0B6
P2860
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Emerging tumefactive multiple ...... rom natalizumab to fingolimod.
@en
Emerging tumefactive multiple ...... rom natalizumab to fingolimod.
@nl
type
label
Emerging tumefactive multiple ...... rom natalizumab to fingolimod.
@en
Emerging tumefactive multiple ...... rom natalizumab to fingolimod.
@nl
prefLabel
Emerging tumefactive multiple ...... rom natalizumab to fingolimod.
@en
Emerging tumefactive multiple ...... rom natalizumab to fingolimod.
@nl
P2860
P356
P1476
Emerging tumefactive multiple ...... rom natalizumab to fingolimod.
@en
P2093
Bernd Turowski
Sebastian Jander
P2860
P304
P356
10.1177/1352458512463768
P577
2012-11-01T00:00:00Z